Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupUrologic OncologyDiseaseBladder CancerRenal Pelvic CarcinomaSubgroupICD10C65C67.-MeSHCarcinoma, Transitional CellUrinary Bladder NeoplasmsUrogenital NeoplasmsUrologic NeoplasmsSequenceCheckMate 901: NIVO360/GEMC1000/CISP70, Urinary Bladder Ca (PID2490) -|- NIVO480 Maint. (PID2491)JAVELIN Bladder 100: GEMC1000/CISP70, urinary bladder Ca (PID544) -|- AVEL800, maint. (PID679)ChemotherapyChemo-substanceCisplatinGemcitabineNivolumabPaclitaxelChemo-substanceCisplatinGemcitabineNivolumabPaclitaxelChemo-substanceCisplatinGemcitabineNivolumabPaclitaxelChemo-substanceCisplatinGemcitabineNivolumabPaclitaxelNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances1710Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlBleedingConstipationDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHypothyroidismInfectionsLeukopeniaMucositisNeutropeniaPruritusRenal FailureThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorBellmunt Jvan der Heijden MS von der Maase HDiseaselokal fortgeschrittenes oder metastasiertes Urothelkarzinom, ohne Vorbehandlung, ECOG 0-1TCC des Urothels, fortgeschr. oder metastasiert, ErstlinieUrothelkarzinom, fortgeschritten oder metastasiert, Erstlinie, ECOG 0-1OriginArhus University Hospital, DänemarkNetherlands Cancer Institute, Amsterdam, CheckMate 901 TrialVall d’Hebron University Hospital and University Hospital del Mar, BarcelonaProtocols in Revision 4 protocols foundProtocols under revision.Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID544 V1.1)Nivolumab 360 / Gemcitabine 1000 / Cisplatin 70 - Nivolumab 480 Maintenance, Bladder Cancer (PID2491 V1.0)Nivolumab 360 / Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID2490 V1.0)Paclitaxel 80 / Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID1359 V1.3)
